VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Vaccine Mechanisms
Vaximmutordb
Vaxism
Vaxar
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UMMS Logo

Vaccine Detail

MVA85A prime and BCG boost
Vaccine Information
  • Vaccine Name: MVA85A prime and BCG boost
  • Target Pathogen: Mycobacterium tuberculosis
  • Target Disease: Tuberculosis
  • Vaccine Ontology ID: VO_0004106
  • Type: Subunit vaccine
  • Antigen: Mycobacterial mycolyl transferase Ag85A (Vordermeier et al., 2004).
  • FbpA (Ag85A) gene engineering:
    • Type: Recombinant virus expressing Ag85A
    • Description:
    • Detailed Gene Information: Click Here.
  • Virulence: MVA is avirulent in normal and immunocompromised animals and has shown no significant side-effects in 120,000 vaccinated humans. Recombinant fowlpox FP9 cannot replicate in mammalian cells and is not pathogenic in mammals or birds (Vordermeier et al., 2004).
Host Response

Cattle Response

  • Host Strain: Friesians, 6-mo. old
  • Vaccination Protocol: Groups of four calves were subjected to one of five schedules in the first experiment: Group 1: MVA85A was administered at week 0, followed by BCG at week 9. Group 2: BCG Pasteur was administered at week 0, followed by MVA85A at week 9. Group 3: BCG administered at week 0, FP85A (fowlpox) administered at week 8, followed by MVA85A at week 10. Group 4: FP85A administered at weeks 0 and 3, followed by MVA85A at week 8. Group 5: (treatments reversed versus group 4): MVA85A administered at weeks 0 and 3, followed by FP85A at week 8 (Vordermeier et al., 2004). A 106 CFU dose of BCG was injected subcutaneously in side of neck with 1 ml PBS. MVA8A and FP85A doses were each administered as 109 plaque-forming units (PFUs) in PBS in a total 0.1 mL injection volume at each injection site. Animals skin tested with SICCT 14 weeks post-first vaccination (Vordermeier et al., 2004). In the second experiment, six calves were vaccinated s.c. with 106 CFU BCG Pasteur in 1 ml PBS. Three calves each were revaccinated with either a 109 PFU dose of MVA85 (intradermal) or 106 CFU dose of BCG Pasteur, 5 weeks later (Vordermeier et al., 2004).
  • Immune Response: Prime-boost protocols, using recombinant MVA and BCG in combination (groups 1-3), resulted in significantly higher frequencies of Ag85-specific IFN-gamma-secreting cells than the two viral vectors used in combination (P=0.0055), or BCG used alone (groups 2 and 3, P=0.04) (Vordermeier et al., 2004).
References
Vordermeier et al., 2004: Vordermeier HM, Rhodes SG, Dean G, Goonetilleke N, Huygen K, Hill AV, Hewinson RG, Gilbert SC. Cellular immune responses induced in cattle by heterologous prime-boost vaccination using recombinant viruses and bacille Calmette-Guerin. Immunology. 2004 Jul; 112(3); 461-70. [PubMed: 15196215].